Notice: refund approved | Apr 15, 2024 | PAPER | BOARD |
Petitioner's Request for Refund of Post-Institution Fees | Apr 11, 2024 | PAPER | PETITIONER |
Termination Decision: Pre-DI settlement | Mar 4, 2024 | PAPER | BOARD |
Joint Motion to Terminate Proceeding | Mar 1, 2024 | PAPER | PETITIONER |
Confidential Settlement Agreement | Mar 1, 2024 | EXHIBIT | PETITIONER |
Joint Motion to Treat Settlement Agreement as Business Confidential | Mar 1, 2024 | PAPER | PETITIONER |
Exhibit 3001 | Feb 28, 2024 | EXHIBIT | BOARD |
Patent Owner's Updated Mandatory Notices | Jan 18, 2024 | PAPER | PATENT OWNER |
DECISION Granting Patent Owner’s Motions for Admission Pro Hac Vice of Roger J. Chin 37 C.F.R. § 42.10 | Jan 16, 2024 | PAPER | BOARD |
Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Roger J. Chin | Jan 8, 2024 | PAPER | PATENT OWNER |
Ex. 2001 Decl. of Roger J. Chin iso PHV Admission | Jan 8, 2024 | EXHIBIT | PATENT OWNER |
Patent Owner's Exhibit List | Jan 8, 2024 | PAPER | PATENT OWNER |
Notice : Power of Attorney | Dec 13, 2023 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Dec 13, 2023 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Nov 28, 2023 | PAPER | BOARD |
EX-1003 - NCT-236 A Study to Evaluate the Safety and Efficacy | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1004 - 2017.02.25 Internet Archives - Stelara label 761044lbl | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1005 - Updated Ochsenkuhn JCC Abstract | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1006 - Vedolizumab label Entyvio_VMB245 R1_FULL INFORMATION_300 mg_2014 | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1007 - Adalimumab label Humira | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1008 - Infliximab label | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1009 - Danese & Fiocchi, Ulcerative Colitis, N Engl J Med., 365:1713- 25 | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1010 - Cote- Daigneault, Biologics in inflammatory bowel disease... | Nov 22, 2023 | EXHIBIT | PETITIONER |
Exhibit 1011 - Ahern et al., Interleukin-23 Drives Intestinal Inflammation. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1012 - Uhlig et al., Differential Activity of IL-12 and IL-23... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1013 - Yen et al., IL-23 is essential for T cell-mediated colitis and... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1014 - Aggeletopoulou et al., Interleukin 12/interleukin 23 pathway... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1015 - Pedersen et al., Inflammatory pathways of importance for... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1016 - Coskun et al., Novel Targeted Therapies for Inflammatory Bowel... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1017 - Sandborn et al., A Randomized Trial of Ustekinumab... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1018 - U.S. Patent No. 6,902,734 B2 issued to Giles-Komar et al. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1019 - U.S. Patent No. 7,166,285 B2 issued to Giles-Komar et al. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1020a -Application for Extension re U.S. Patent 6,902,734 (part 1 of 3) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1020b -Application for Extension re U.S. Patent 6,902,734 (part 2 of 3) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1020c -Application for Extension re U.S. Patent 6,902,734 (part 3 of 3) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1021 -Application for Extension of Patent Term for U.S. Patent 7,166,285 | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1022 - Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1023 - Webarchive screenshots of www.pmda.go.jp/english/index.html | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1024 - Stelara Prescribing Information (Sept. 2009) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1025 - U.S. Patent Publication No. US 2009/0181027 A1 (’027- Publ.) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1026 - Feagan et al., Ustekinumab as Induction and Maintenance Therapy. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1027 - Janssen R & D NCT02407236 Clinical Protocol (Apr. 20, 2016) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1028 - Affidavit of Nathaniel E Frank-White | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1029 -Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1030 -Field Trials of Health Interventions: A Toolbox, 2015, pp. 200-201 | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1031 - Sands et al., Ustekinumab as Induction and Maintenance Therapy... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1032 - Janssen Announces U.S. FDA Approval of STELARA (ustekinumab)... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1033 - Tarr et al., Superheroes in autoimmune warfare: Biologic... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1035 - Afonso et al., CP-202 Ustekinumab treatment in refractory... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1036a - Excerpts from U.S. Patent 10,961,307 file history (1 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1036b - Excerpts from U.S. Patent 10,961,307 file history (2 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1038 - FDA Approves STELARA (Ustekinumab) for Treatment... (9/26/2016) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1041 - American of College of Rheumatology: Ustekinumab (Stelara) (2018) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1042 - D’Haens et al., A Review of Activity Indices and Efficacy End... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1043 - Dhanda et al., Can Endoscopy Be Avoided in the Assessment... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1044 - Glossary of Common Site Terms, ClinicalTrials.gov (Oct. 2021) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1045 - Outcome Measure Considerations for Clinical Trials Reporting... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1046 - History of Changes for Study: NCT02407236, ClinicalTrials.gov | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1047 - History of Changes for Study 2: NCT02407236, ClinicalTrials.gov | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1048 - Kim et al., Correlation between Histological Activity... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1049a -U.S. Patent Application Publication 2020/0262908 A1 (part 1 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1049b -U.S. Patent Application Publication 2020/0262908 A1 (part 2 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1050 - Pithadia & Jain, Treatment of inflammatory bowel disease (IBD) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1051 - Higgins et al., Is Endoscopy Necessary for the Measurement... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1052a - WO 2017/049035 A1 (“WO 2017/049035”) (part 1 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1052b - WO 2017/049035 A1 (“WO 2017/049035”) (part 2 of 2) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1053 - WO 2015/119841 A1 issued to Zuniga et al. (“WO 2015/119841”) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1054 - History of Changes for Study: NCT02407236, ClinicalTrials.gov | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1055 - Stelara, European Medicines Agency | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1056 - Nakov et al., Correlation between Ulcerative Colitis Endoscopic | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1060 - A Safety and Efficacy Study for Infliximab (Remicade) in Patients | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1061 - Efficacy and Safety of Adalimumab in Subjects With Moderately... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1062 - Study of Vedolizumab (MLN0002) in Patients With Moderate to... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1063 - Sequence published with WO 2015/119841 A1 issued to Zuniga et al. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1064 - A Study to Evaluate the Safety and Efficacy of Ustekinumab... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1065 - webarchive of Chemical Database for Ustekinumab | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1066 - webarchive of Label: STELARA - ustekinumab injection, solution | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1067 - Webarchive of Label: STELARA - ustekinumab injection, solution | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1068 - Labeling Archives, search results for ustekinumab - 2016 STELARA | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1069 STELARA- ustekinumab solution Archived Drug Label )Sept. 2016) | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1070 - Ustekinumab (Stelara), Ottawa (ON): Canadian Agency for Drugs... | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1071 - Declaration of Noah S. Frank | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1072 - Listing of Challenged Claims of the 10,961,307 patent | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1034 - Kolios et al., Paradoxical ulcerative colitis during adalimumab.. | Nov 22, 2023 | EXHIBIT | PETITIONER |
EX-1001 - U.S. Patent 10.961,307 | Nov 22, 2023 | EXHIBIT | PETITIONER |
Notice : Petitioner's Power of Attorney | Nov 22, 2023 | PAPER | PETITIONER |
Ex-1002-Declaration of Alan Victor Safdi | Nov 22, 2023 | EXHIBIT | PETITIONER |
IPR Petition (307) | Nov 22, 2023 | PAPER | PETITIONER |